Skip to content

Study on adjuvant therapy of adenomyosis with Xueping Tablet: a randomized controlled trial.

Study on adjuvant therapy of adenomyosis with Xueping Tablet

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039516
Enrollment
Unknown
Registered
2020-10-30
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis

Interventions

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
28 Years to 48 Years

Inclusion criteria

Inclusion criteria: 1. Women who meet the diagnostic criteria for adenomyosis, aged 28-48 years old, are non-menopausal and non-lactating; 2. Those who voluntarily participate in this experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Gnrh-a and steroid hormone use history within 3 months; 2, levonorgestrel or iUD placement contraindications; 3. Patients with cardiovascular and cerebrovascular diseases, liver, kidney, diabetes, tumor and other serious diseases; 4. Mental illness patients and long-term drinking or taking drugs affect cognition; 5. Patients with coagulation dysfunction or previous thrombotic diseases; 6. Participating in other drug clinical subjects; 7. Had a history of allergy to Traditional Chinese medicine.

Design outcomes

Primary

MeasureTime frame
The degree of dysmenorrhea;

Secondary

MeasureTime frame
Rate of surgery;

Countries

China

Contacts

Public ContactYu Chaoqin

Shanghai Changhai Hospital

chaoqyu81@163.com+86 13818390984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026